Form 4: Lenz Therapeutics CFO Acquires 200,000 Stock Options

Daniel R. Chevallard, CFO of Lenz Therapeutics, acquired 200,000 stock options on March 21, 2024, according to a Form 4 filing with the SEC.

Summary

• Daniel R. Chevallard, the Chief Financial Officer of Lenz Therapeutics, Inc., filed a Form 4 with the SEC on March 25, 2024.
• The filing reports a transaction that occurred on March 21, 2024, where Chevallard acquired 200,000 stock options.
• These options have an exercise price of $15.05.
• The options vest over time, with 25% vesting on the one-year anniversary of the Vesting Commencement Date (March 21, 2024), and the remaining shares vesting monthly thereafter over 36 months.
• The options expire on March 20, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The acquisition of options by an executive could be interpreted as a positive signal, but it's a routine event.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The vesting schedule is tied to continued service as a 'Service Provider', so there is a risk if the reporting person leaves the company before the options are fully vested.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the biotech industry.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a minor positive impact on shareholder sentiment.

Key Dates